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Cisplatin is a chemotherapeutic agent that induces tumor
necrosis factor-a (TNF-a) production in many cell types with
unfortunate renal toxicity. We sought to determine the
contributions of renal parenchymal cells and bone
marrow-derived immune cells to the pathogenesis of
cisplatin-induced renal injury in vivo. To do this we created
chimeric mice in which the bone marrow was ablated and
replaced with donor bone marrow cells from wild-type or
from TNF-a knockout mice. Six weeks after reconstitution, the
chimeric mice were treated with cisplatin and renal structural
and functional parameters were measured. Chimeras with
kidneys of wild-type animals all developed significant renal
failure after 72 h of cisplatin treatment regardless of the
immune cell source. Chimeras with kidneys of TNF-a
knockout mice showed significantly less renal dysfunction
(blood urea nitrogen, serum creatinine, and glomerular
filtration rate), renal histologic injury, and serum TNF-a levels;
again regardless of the immune cell source. Urinary excretion
of several proinflammatory cytokines was lower in the
wild-type bone marrow-knockout kidney chimera mouse
than in wild-type background mice. Our results indicate that
a substantial portion of circulating and urinary TNF-a is
derived from nonimmune cells after cisplatin administration.
We conclude that the production of TNF-a by renal
parenchymal cells, rather than by bone marrow-derived
infiltrating immune cells, is responsible for cisplatin-induced
nephrotoxicity.
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Cisplatin is a common and effective chemotherapeutic agent
for the treatment of many types of cancer. An unfortunate
consequence of cisplatin treatment is renal toxicity which
affects 25–35% of treated patients.1 Studies from our
laboratory2,3 and others4,5 have demonstrated that tumor
necrosis factor-a (TNF-a) production is increased in cisplatin
toxicity. We also demonstrated that TNF-a plays a pathogenic
role in stimulating cytokine and chemokine expression in the
kidney and in producing acute renal failure.2 Specifically,
genetic deletion of TNF-a or pharmacologic inhibition of
TNF-a action reduced the expression of inflammatory
cytokines and chemokines (e.g. TNF-a, monocyte chemo-
tactic protein-1 (MCP-1), and regulated upon activation
normal T-cell expressed and secreted (RANTES)) and
preserved renal function after cisplatin injection. These
effects of TNF-a were determined to be mediated via the
TNFR2 receptor subtype.3
Although these studies indicated that TNF-a gene
expression and protein content within the kidney increased
after cisplatin administration, the source of the TNF-a which
was responsible for renal injury was unclear. TNF-a is
produced by a broad range of tissues and cells, including
immune cells and intrinsic renal cells, such as mesangial
cells,6 glomerular7,8 and tubular epithelial cells,9–11 and
endothelial cells.12,13 The extent to which infiltrating immune
cells and intrinsic renal cells produce TNF-a and mediate
nephrotoxicity in response to cisplatin is not known.
Therefore, the purpose of the present study was to determine
the relative contribution of TNF-a produced by renal
parenchymal cells vs leukocytes in mediating cisplatin-
induced renal injury in vivo. We created chimeric mice in
which TNF-a can be produced by either resident kidney cells
or circulating immune cells. We evaluated kidney function,
histology, and cytokine expression in these chimeric mice
following cisplatin administration. The results indicate the
local production of TNF-a by resident kidney cells is crucial
in cisplatin-induced nephrotoxicity.
RESULTS
Chimeric mice were created to examine the differential role
of leukocyte-derived versus kidney-derived TNF-a in the
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pathogenesis of cisplatin nephrotoxicity. First, it was
important to show that the bone marrow transplantation
procedure resulted in a high degree of chimerism, did not
alter the distribution of circulating leukocyte subtypes, and
did not impact the ability of circulating immune cells to
produce TNF-a (Figure 1). To determine the extent of
chimerism, enhanced green fluorescent protein (EGFP) was
used as a marker of the donor bone marrow. Figure 1a shows
the results of flow cytometry of peripheral blood obtained
from nontransplanted EGFP-expressing transgenic mice and
from chimeric mice in which EGFP bone marrow was
transplanted into non-EGFP expressing C57BL6 mice. The
frequency of EGFP-positive cells in the two sets of mice was
virtually identical, indicating almost complete replacement
(498%) of the recipient circulating leukocytes by donor
cells. As studies have indicated a role for neutrophils and B
and T lymphocytes in the development of acute renal failure,
the effect of bone marrow transplantation on the distribution
of various subtypes of peripheral blood leukocytes was
determined. Two-color flow cytometry was performed on
leukocytes stained for a common leukocyte antigen (CD45)
and markers for CD4 and CD8 lymphocytes, B cells,
macrophages, NK cells, and neutrophils. The distribution
of each subtype, as a percentage of CD45-positive cells, was
the same in nontransplanted and chimeric mice (Table 1).
Next, intracellular cytokine staining was used to determine
the ability of transplanted immune cells to produce TNF-a.
Peripheral blood leukocytes were obtained from either EGFP-
expressing transgenic mice or TNF-a knockout mice that had
been transplanted with EGFP bone marrow 6 weeks earlier
(Figure 1b). Cells were stimulated in vitro to produce TNF-a,
fixed, permeabilized, and stained with TNF-a antibodies as
described in the Materials and Methods. Flow cytometry was
used to determine the levels of EGFP expression and TNF-a
content. As shown in Figure 1b and c, approximately 26% of
circulating EGFP-positive cells in both sets of mice stained
positive for TNF-a. This result indicates that the bone marrow
transplantation procedure itself did not impair TNF-a
production by the donor immune cells.
Next, bone marrow chimeric mice were treated with
cisplatin (20 mg/kg body weight) or saline and assessed for
renal dysfunction. As shown in Figure 2, WT-WT chimeric
mice developed severe renal failure between 48 and 72 h. The
degree of renal dysfunction at 72 h (BUN 140710 mg/dl, and
creatinine 1.1270.10 mg/dl) was similar to what we have
observed in nontransplanted wild-type mice2,3,14 and suggests
that the bone marrow transplant procedure itself does not
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Figure 1 | Functional reconstitution of immune system by donor
bone marrow. (a) Extent of chimerism was determined by flow
cytometry of peripheral blood using EGFP as a marker of donor cells.
The left-hand bar represents EGFP-positive cells in the blood of
nontransplanted EGFP transgenic mice. The right-hand bar are cells
from C57BL6 mice which were transplanted with bone marrow from
EGFP transgenic mice (data are %7s.d. of gated events, n¼ 3 in each
group). (b and c) Intracellular cytokine staining for TNF-a production
by peripheral blood leukocytes from a nontransplanted EGFP
transgenic mouse (b) or a TNF-a knockout mouse transplanted with
bone marrow from EGFP transgenic mice. Representative of results
from three animals in each group.
Table 1 | Distribution of circulating leukocytes in nontransplanted and chimeric mice
CD4 CD8 B cells Macrophages NK cells Neutrophils
WT (C57BL6) 10.971.6 10.272.6 51.379.1 0.970.5 1.570.4 12.577.7
WT-WT 13.071.4 9.871.4 59.376.5 0.670.2 1.070.3 8.174.1
P=NS P=NS P=NS P=NS P=NS P=NS
ANOVA, analysis of variance; NK cells, natural killer cells; NS, not significant.
All data are %7s.d. of CD45(+) cells. N=3 in each group. P-values were calculated by ANOVA.
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Figure 2 | Cisplatin nephrotoxicity in WT-WT (’), KO-WT (K),
WT-KO (m) and KO-KO (.) chimeric mice. Bone marrow
chimeric mice were injected with 20 mg/kg cisplatin at time¼ 0.
Blood urea nitrogen and creatinine were measured at the indicated
times. (*Po0.05 vs WT-WT and KO-WT n¼ 8–11).
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affect the susceptibility to cisplatin-induced acute kidney
injury. Of note, KO-WT mice developed similar degrees of
renal failure as the WT-WT mice. In contrast, mice with a
recipient TNF-a knockout background, whether they were
transplanted with wild-type (WT-KO, BUN 60711 mg/dl,
and creatinine 0.3370.05 mg/dl) or TNF-a knockout bone
marrow (KO-KO, BUN 60713 mg/dl, and creatinine
0.570.07 mg/dl) had substantially less renal failure than the
mice with a wild-type background (Po0.01, n¼ 6–12). The
results in the KO-KO group confirm our earlier report that
TNF-a knockout mice are resistant to cisplatin nephrotoxicity.2
GFR was also determined by fluorescein isothiocyanate
(FITC)-inulin clearance as a more precise measure of renal
function. As shown in Figure 3, mice with a wild-type
background had severely reduced GFR 72 h after cisplatin
treatment (WT-WT 1874.5 ml/min, KO-WT 38713 ml/
min), whereas mice with a TNF-a knockout background,
regardless of the genotype of their immune cells, had well-
preserved renal function (KO-KO 19677 ml/min, WT-
KO 181714 ml/min, Po0.01 vs WT-WT or KO-WT,
n¼ 3 in each group).
The functional abnormalities in the chimeric mice were
also reflected by structural changes in the kidney. Thus, 72 h
after cisplatin treatment, kidneys with a wild-type back-
ground (WT-WT or KO-WT) showed severe tubular
injury as evidenced by cast formation, loss of brush border
membranes, sloughing of tubular epithelial cells, and dilation
of tubules (Figure 4). These changes were minimal in kidneys
from animals with a TNF-a knockout background (WT-
KO, KO-KO). Semiquantitative assessment of histologic
injury yielded tubular necrosis scores 3.170.2 in cisplatin-
treated WT-WT mice, 2.870.2 in KO-WT mice, 1.570.4
in WT-KO mice, and 1.170.4 in KO-KO mice. The
differences between wild-type background mice and TNF-a
knockout background mice were significant (Po0.01,
n¼ 8–11).
Leukocyte infiltration was measured using the napthol
AS-D chloroacetate esterase stain. Thirty  40 fields of
esterase-stained sections were examined for quantitation
of leukocytes. As shown in Figure 5, cisplatin injection
produced a large increase in leukocytes within the kidney
cortex in wild-type background chimeric mice (WT-WT
173763, KO-WT 107741). In contrast, TNF-knockout
background mice (KO-KO 1672, WT-KO 56718) had
significantly fewer infiltrating leukocytes (Po0.01, n¼ 6–8).
These results indicate that local production of TNF-a by
resident renal cells is crucial to the recruitment of leukocytes
to the kidney in cisplatin-induced nephrotoxicity.
Cisplatin administration results in the upregulation of a
number of proinflammatory cytokines and chemokines in
the kidney. This upregulation was blunted in TNF-a knock-
out mice.2 Accordingly, we examined the expression of these
cytokines in the TNF-a chimeric mice. Real-time reverse
transcriptase-polymerase chain reaction (RT–PCR) was used
to measure renal expression of certain inflammation-related
genes (Figure 6). We previously demonstrated that Heme
oxygenase 1, IL-1b, TNF-a, TNFR2, and MCP-1 are
upregulated in the kidney after cisplatin injection.2,3,14 These
responses were preserved in mice with a wild-type back-
ground (WT-WT and KO-WT) but were blunted in mice
which lacked the ability to produce TNF-a in their kidneys
(WT-KO and KO-KO).
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Figure 3 | GFR in cisplatin-treated chimeric mice measured using
FITC-labeled inulin. WT-WT (’), KO-WT (K) chimeric mice
showed significantly decreased GFR as compared with WT-KO (m)
and KO-KO (.) mice. Data are expressed as mean7s.e.m. (n¼ 3–4).
*Po0.05 vs WT-WT and KO-WT.
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Figure 4 | Effect of cisplatin on kidney morphology in chimeric
mice. Periodic acid-Schiff-stained sections of kidney removed 72 h
after injection of cisplatin (a–d) or (e) saline. (a and e) WT-WT; (b)
KO-WT; (c) WT-KO; (d). KO-KO. (f) Summary data of tubular
necrosis scores for each group of chimeric mice. *Po0.01 vs WT-WT
and KO-WT, n¼ 8–11.
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Cisplatin treatment increases serum TNF-a levels.2–5,14–16
However, the source of the TNF-a is unknown. To address
this issue, we measured the effect of cisplatin on serum TNF-
a levels in the chimeric mice (Figure 7). Cisplatin injection
increased serum TNF-a levels in WT-WT (158728 pg/ml)
and KO-WT (251760 pg/ml) mice. However, TNF-a levels
were lower in WT-KO (90717 pg/ml, Po0.01, n¼ 4–5)
mice and, as expected, undetectable in KO-KO mice. These
results indicate that a large portion of circulating TNF-a after
cisplatin injection is derived from cells of nonimmune origin.
We next measured cytokine and chemokine levels in the
urine. As described in the Materials and Methods section, 16
cytokines were measured simultaneously in the urine using a
multiplexed cytokine immunoassay. Upon cisplatin treat-
ment, as shown in Figure 8, TNF-a, IP-10, IL-2, IL-6, and
RANTES were detected in the urine. Of note, wild-type
background mice secreted a large amount of TNF-a in urine.
In contrast, there was no detectable TNF-a in the urine of
mice deficient of TNF-a in their kidneys. These results
suggest that resident renal cells are the major source of
urinary TNF-a production. Likewise, mice with a recipient
TNF-a knockout background had less urinary excretion
of IL-2 and RANTES, suggesting that renal production of
TNF-a is a stimulus for the renal production and excretion of
these cytokines.
DISCUSSION
In the murine model of cisplatin nephrotoxicity, cisplatin
increases plasma and urine levels of TNF-a and increases
renal expression of TNF-a mRNA. Moreover, TNF-a was
shown to play a pathogenic role in cisplatin nephrotoxicity.2
However, the source of TNF-a which contributes to acute
renal injury is not clear. In this regard, TNF-a is produced by
a broad range of tissues and cells, including immune cells and
intrinsic renal cells, such as mesangial cells,6,17 glomerular7,8
and tubular epithelial cells,9–11 and endothelial cells.12,13 As
cisplatin nephrotoxicity is associated with the influx of bone
marrow-derived inflammatory cells into the kidney,2,3,9,14
these infiltrating leukocytes could be the source of intrarenal
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Figure 5 | TNF-a mediates leukocyte infiltration in
cisplatin-induced nephrotoxicity. Sections of kidney harvested
72 h after injection of (a–d) cisplatin or (e) saline were stained for
neutrophils as described in the Materials and Methods section.
(a and e) WT-WT; (b) KO-WT; (c) WT-KO; (d) KO-KO.
Neutrophils are seen as brown staining. Original magnification of all
images is  400. (f) Summary data of leukocyte infiltration for each
group of chimeric mice Thirty  40 fields of kidney cortex were
examined from each animal. The total number of leukocytes in those
30 fields is presented. *Po 0.01 vs WT-WT and KO-WT, n¼ 6–8.
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Figure 6 | Cisplatin-induced gene expression in chimeric mice.
Cytokine gene expression was measured 72 h after injection of
cisplatin by RT–PCR. The expression levels were normalized to the
expression of actin and are expressed relative to saline-treated
chimeric mice of the same genotypes. WT-WT (black) KO-WT
(open), WT-KO (gray), KO-KO (hatched), *Po0.01 vs WT-KO and
KO-KO, n¼ 3.
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Figure 7 | Serum TNF-a 72 h after cisplatin injection in chimeric
mice. The levels of TNF-a in serum were measured using an ELISA
assay. *Po0.01 vs WT-WT and KO-WT n¼ 6–8.
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and circulating TNF-a. On the other hand, we have shown that
cisplatin stimulates renal epithelial cells to produce TNF-a
in vitro9,14 raising the possibility that renal parenchymal cells
are the major source of TNF-a in cisplatin nephrotoxicity.
These studies were performed to determine the role of
leukocyte-derived vs kidney-derived TNF-a in the pathogen-
esis of cisplatin nephrotoxicity. The approach used was to
create chimeric mice in which the TNF-a gene was disrupted
in cells of bone marrow origin or the kidney. This approach
has been used to determine the importance of leukocyte
TNFR2 expression in experimental hepatitis.18 An analogous
approach has also been successfully employed to determine
the site of TNF-a production in crescentic glomerulonephri-
tis19 and of adenosine agonist action20 and P-selectin
production21 in ischemic acute renal failure.
The main finding of the current studies was that chimeric
mice produced from wild-type recipients were equally
susceptible to cisplatin nephrotoxicity regardless of whether
their immune systems were from wild-type or TNF-a-
deficient donors. In contrast, chimeras of TNF-a knockout
recipients were resistant to nephrotoxicity regardless of the
origin of their immune systems (Figures 1–3). The lack of
renal failure in the WT-KO mice can not be attributed to
faulty production of TNF-a by the transplanted cells because
we demonstrated that transplanted cells retain their ability to
produce TNF-a (Figure 1) and circulating levels of TNF-a
were detectable in the WT-KO mice (Figure 7). These
results indicate that, despite the fact that cisplatin nephro-
toxicity is characterized by the infiltration of inflammatory
cells, TNF-a produced by bone marrow-derived cells does not
contribute to cisplatin nephrotoxicity. Rather, production of
TNF-a by renal parenchymal cells is probably responsible for
the renal failure.
We also noted that the influx of leukocytes into the kidney
was reduced in WT-KO and KO-KO mice compared with
KO-WT and WT-WT mice (Figure 5). This result
indicates that the local production of TNF-a by resident
kidney cells promotes an inflammatory response within the
kidney. As both renal injury and leukocyte infiltration were
reduced in mice with a TNFa-deficient background, our
results do not establish if the reduction in the inflammatory
infiltrate was the cause or the result of lessened kidney injury.
Recent work from Rabb’s group, however, demonstrated that
early infiltration of the kidney by T cells is an important
precedent to cisplatin injury.22 In that study, deletion of T
cells reduced cisplatin-induced renal dysfunction and also
reduced kidney TNF-a content and infiltration of neutrophils
and macrophages.22 Our results indicate that the actions of T
cells in cisplatin nephrotoxicity are not dependent upon the
elaboration of TNF-a by those cells. Kidney expression of
several chemokines and adhesion molecules is increased by
cisplatin.2 In this regard, expression of MCP-1 was increased
in WT-WT mice but not in WT-KO or KO-KO mice.
Likewise, cisplatin increased the urinary excretion of
RANTES in WT–WT mice but not in the other chimeras.
The expression of intercellular adhesion molecule-1 (ICAM1)
(not shown) was modestly increased in WT-WT, WT-KO,
and KO-WT mice, but not in KO-KO mice. Thus, both
renal and extrarenal production of TNF-a regulates the
expression of different chemotactic factors and may account
for the decreases in renal leukocyte infiltration seen in the
WT-KO and KO-KO mice.
Cisplatin increases both serum and urine concentrations of
TNF-a.2,4,22 Cisplatin has been shown to increase TNF-a
production by renal proximal tubule cells9 and by macro-
phages.23 We found that serum levels of TNF-a were elevated
to a similar extent in WT-WT and KO-WT mice but were
significantly lower in WT-KO mice (Figure 6), indicating
that the majority, but not all, of circulating TNF-a seen in
cisplatin-treated mice has a nonimmune origin. The finding
that cisplatin modestly increased serum TNF-a levels in
WT-KO mice is consistent with previous reports demon-
strating a cisplatin-induced increase in TNF-a production
by certain immune cells.23,24 Although a source other than
the kidney can not be excluded on the basis of the present
studies, we did not detect increases in TNF-a mRNA in brain,
heart, liver, or skeletal muscle of cisplatin-treated mice
(unpublished data). As demonstrated previously,2 urinary
excretion of TNF-a increased in cisplatin-treated WT-WT
mice (Figure 8). Urinary TNFa was decreased in both the
KO-WT and WT-KO mice suggesting that both immune
and renal parenchymal cells contribute to urinary TNF-a. The
lower TNFa excretion in KO-WT mice compared with
WT-WT mice, in spite of comparable serum TNF-a levels
and GFR suggests that urinary TNF-a derives mainly from
intrarenal production (either by parenchymal cells or immune
cells) and secretion rather than by glomerular filtration.
Although our results indicate that renal parenchymal
production of TNF-a is critical to the development of
nephrotoxicity, the precise site of TNF-a production within
the kidney in the setting of cisplatin nephrotoxicity remains
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Figure 8 | Cisplatin-induced urine cytokine/chemokine profile in
chimeric mice. Urine cytokine/chemokine excretion at 72 h was
evaluated using a bead-based multiple cytokine assay. Levels of
cytokines were normalized to creatinine. Black bars represent saline-
treated WT-WT mice; the remaining bars are cisplatin-treated mice –
WT-WT (open), KO-WT (gray), WT-KO (striped), KO-KO (cross-
hatched). ND, not detected. *Po0.01, vs cisplatin-treated WT-WT,
n¼ 4–5.
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uncertain. Several cell types within the kidney are capable of
producing TNF-a,6,7,12,13 including proximal tubule cells.10,11
We have shown that cisplatin increases TNF-a production by
proximal tubule cells in vitro.9 However, our attempts to
localize TNF-a production by immunofluorescence and
immunohistochemistry have not been successful (unpub-
lished results). This difficulty might reflect continuous
secretion of TNF-a as it is produced. In any case, the present
data do not allow us to draw any conclusions about the site of
intrarenal TNF-a production.
The utility of urinary cytokine levels as early biomarkers of
acute kidney injury is under investigation. In patients
receiving kidney transplants, Kwon et al.25 found that urinary
levels of interleukin (IL)-6 and IL-8 predicted the duration of
delayed allograft function. Parikh et al.26 found that elevated
urinary IL-18 predicted the onset of acute kidney injury in
patients with respiratory distress syndrome. In a murine
model of ischemic acute kidney injury, the urinary excretion
of the chemokine KC increased before an elevation in the
serum creatinine.27 These studies are the first to examine the
excretion of urinary cytokines in cisplatin acute kidney
injury. We found that, in addition to TNF-a, cisplatin
resulted in significant increases in the excretion of several
cytokines and chemokines, including IL-2, IL-6, and
RANTES. The data in Figure 8 are from 72 h after cisplatin
injection, when renal failure is well established. Further
studies at earlier time points will be required to determine
the time course of cytokine excretion after cisplatin treatment
and its possible predictive value in humans. Also, excretion of
IL-2 and RANTES was greatest in WT-WT mice and
considerably reduced in the other chimeras, suggesting a role
for TNF-a in their renal excretion. On the other hand,
urinary IL-6 was markedly elevated in all of the chimeras,
even the KO-KO mice that sustained relatively little injury.
Accordingly, urinary IL-6 may be a nonspecific response to
cisplatin administration, per se, or is sufficiently sensitive to
be increased by the less severe injury in the KO-KO mice.
Further studies will be needed to distinguish between these
possibilities.
In summary, we have demonstrated that the production of
TNF-a by bone marrow-derived immune cells is not critical
for the development of cisplatin nephrotoxicity. Rather, local
production of TNF-a by renal parenchymal cells likely
promotes the elaboration of chemokines and an influx of
inflammatory cells resulting in functional and structural
damage. In addition, the urinary excretion of several
proinflammatory cytokines and chemokines is increased in
cisplatin-treated animals. Further studies will be needed to
determine the precise cellular source of TNF-a production
within the kidney and the possible role of urinary cytokine
levels as biomarkers of cisplatin nephrotoxicity.
MATERIALS AND METHODS
Creation of chimeric mice
Chimeric mice were created using C57BL/6 mice (Jackson
Laboratories, Bar Harbor, ME, USA), mice expressing EGFP under
control of the actin promoter (C57BL/6-TgN(ACTbEGFP)10sb, also
from the Jackson Laboratories) and mice with a deletion of the
TNF-a gene (B&K Universal, Ltd, East Yorkshire, UK) as either bone
marrow donors or recipients. Donor mice were killed with sodium
pentobarbital and the femurs were removed and flushed with RPMI
medium containing 10% fetal calf serum to obtain bone marrow
cells. Unfractionated bone marrow cells were washed and resus-
pended in phosphate-buffered saline at a concentration of 20
million cells/ml. Recipient C57/EGFP mice and TNF-a knockout
mice (aged 6–7 weeks) were lethally irradiated using a Gammacell
irradiator (two doses of 600 rads, 4 h apart). 8 h after the irradiation,
10 million donor bone marrow cells were injected into the lateral tail
vein of recipients. Four sets of chimeric mice were created: WT-
WT (wild-type donor and recipient; a control for the transplanta-
tion procedure); WT-KO (wild-type donor and TNF knockout
recipient; these mice only express TNF-a in cells of bone marrow
origin); KO-WT (TNF-a knockout donor and wild-type recipient;
these mice express TNF-a normally in all tissues except those of
bone marrow origin); KO-KO (TNF-a knockout donor and
recipient; these mice do not express TNF-a in any tissue and serve as
an additional control to the transplantation process). Mice were
maintained in specific pathogen-free conditions before and after the
bone marrow transplantation.
Drug administration
Cisplatin (Sigma-Aldrich, St Louis, MI, USA) was dissolved in saline
at a concentration of 1 mg/ml and filtered through a 0.2 mm syringe
filter. Mice were given a single intraperitoneal injection of either
vehicle (saline) or cisplatin (20 mg/kg body weight). This dose of
cisplatin produces severe renal failure in mice.2,28 Blood was
collected every 24 h by tail vein bleeding for measurement of urea
nitrogen, creatinine, and TNF-a. Urine was harvested by bladder
massage. Animals were killed at different time intervals, and kidney
tissue was processed for histology and RNA isolation.
Renal function
Renal function was assessed by measurements of blood urea
nitrogen (BUN; VITROS DT60II Chemistry slides, Ortho-clinical
Diagnostics, Rochester, NY, USA) and serum creatinine (DZ072B,
Diazyme Labs, San Diego, CA, USA). GFR in conscious mice was
measured using a single bolus injection of FITC-labeled inulin
(FITC-inulin).29 Briefly, 5% FITC-inulin was dissolved in 0.9% NaCl
and dialyzed. Dialyzed FITC-inulin (3.75 ml/g BW) was injected via
tail vein. Blood samples were collected via saphenous vein at 3, 7, 10,
15, 35, 55, and 75 min post-injection. A serum sample of 10 ml was
buffered with 40 ml HEPES (500 mM, pH 7.4) and fluorescence was
determined using a Fluoroscan Ascent FL with 485 nm excitation,
and 540 nm emission. Serum fluorescence data were fit to a two-
component exponential decay curve using nonlinear regression
(Origin 6.1, Microcal Software Inc., Northhampton, MA, USA).
GFR was calculated using the following equation: GFR¼ I/
(A1*T1þA2*T2) where I is the amount of FITC-inulin delivered
by the bolus injection; A1 and A2 are the y-intercept values of the
two decay rates, and t1 and t2 are the decay constants for the
distribution and elimination phases, respectively.
Intracellular cytokine staining of TNF-a in peripheral blood
The BD Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA, USA)
was used for TNF-a intracellular staining. Briefly, 200ml whole
blood was collected via saphenous vein and diluted with 200ml
Iscove’s modified Dulbecco’s medium. Next, phorbol 12-myristate
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13-acetate (PMA, 50 ng/ml) and ionomycin (1 mg/ml, Sigma) were
added to stimulate TNF-a production followed by a protein
transport inhibitor (BD GolgiPlug, BD Biosciences). After incuba-
tion for 4 h in 5% CO2 at 371C, red blood cells were lysed by adding
2 ml BD PharmLyse solution, BD Biosciences. Leukocytes were
centrifuged and resuspended in 100 ml of staining buffer. BD
Cytofix/Cytoperm solution (500 ml) was added to fix and permea-
bilize the cells followed by addition of a PE-conjugated anti-mouse
TNF-a antibody (1:100 dilution, BD Biosciences). After a 30-min
incubation with the labeled antibody, cells were washed with BD
Perm/Wash solution, centrifuged, and resuspended in 500 ml
phosphate-buffered saline containing 1% fetal bovine serum and
analyzed by flow cytometry.
Quantitation of mRNA by real-time RT–PCR
Real-time RT–PCR was performed in an Applied Biosystems Inc.
7900 Sequence Detection System (Foster City, CA, USA). Total RNA
(1.5 mg) was reverse-transcribed in a reaction volume of 20 ml using
Omniscript RT kit and random primers. The product was diluted to
a volume of 150 ml and either 2 ml (actin) or 10 ml (all others)
aliquots were used as templates for amplification using the SYBR
Green PCR amplification reagent (Applied Biosystems) and gene-
specific primers. The primer sets used were mouse IL-1b (forward:
CTCCATGAGCTTTGTACAAGG; reverse: TGCTGATGTACCAGTT
GGGG), TNF-a (forward: GCATGATCCGCGACGTGGAA; reverse:
AGATCCATGCCGTTGGCCAG); TNFR1 (forward: CCGGGCCA
CCTGGTCCG; reverse: CAAGTAGGTTCCTTTGTG); TNFR2 (for-
ward: GTCGCGCTGGTCTTCGAACTG; reverse: GGTATACATGC
TTGCCTCACAGTC. Heme oxygenase-1 (forward: AGCATGCCCC
AGGATTTG; reverse: AGCTCAATGTTGAGCAGGA). IL-10 (for-
ward: ATG CCT GGC TCA GCA CTG; reverse: GTC CTG CAT TAA
GGA GTC G). MCP-1 (foward: ATGCAGGTCCCTGTCATG;
reverse: GCTTGAGGTGGTTGTGGA). The amount of DNA was
normalized to the b-actin signal amplified in a separate reaction
(forward primer: CATGGATGACGATATCGCT; reverse: CATGAGG
TAGTCTGTCAGGT).
Cytokine/Chemokine quantitation
The levels of TNF-a in serum were quantitated using an ELISA assay
(Quantikine Mouse TNF-a kit; R&D Systems Inc., Minneapolis,
MN, USA). Serum (50 ml) was used for the TNF-a assay. Urine
cytokines and chemokines (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-12 (p70), IL-17, IFN-g, IP-10, G-CSF, TNF-a, MIP-1a, MCP-1,
and RANTES) were measured using a bead-based multiplexed
cytokine analysis kit (Linco Research Inc., St Charles, MO, USA)
using a Luminex-100 system (Luminex Corp. Austin, TX, USA).
Assays were run in duplicate according to the manufacturers’
protocol and data were collected and analyzed using MasterPlex QT
2.5 software (MiraiBio, Alameda, CA, USA). Amounts of cytokines
were normalized to the creatinine concentration in the urine.
Histology and immunohistochemistry
Kidney tissue was fixed in buffered formalin for 24 h and then
embedded in paraffin wax. Five-micrometer sections were stained
with periodic acid-Schiff or naphthol AS-D chloroacetate esterase
(kit no. 91A; Sigma-Aldrich). The esterase stain identifies infiltrating
neutrophils and monocytes. Thirty  40 fields of esterase-stained
sections were examined for quantitation of leukocytes. Tubular
injury was assessed in periodic acid-Schiff-stained sections using a
semiquantitative scale30 in which the percentage of cortical tubules
showing epithelial necrosis was assigned a score: 0¼ normal;
1¼o10%; 2¼ 10–25%; 3¼ 26–75%; 4¼475%. The individual
scoring the slides was blinded to the treatment and strain of the
animal. Immunohistochemistry for neutrophils was performed by
incubating dewaxed sections with a rat anti-murine neutrophil
primary antibody (MCA 771 GA, SeroTec, Raleigh, NC, USA)
followed by a biotinylated anti-rat IgG secondary antibody. Signal
was developed using the avidin/biotin complex peroxidase method
(Pierce, Rockford, IL, USA).
Statistical methods
All assays were performed in duplicate. The data are reported as
mean7s.e.m. Statistical significance was assessed by unpaired, two-
tailed Student t-tests for single comparisons or analysis of variance
for multiple comparisons.
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